TransCode Therapeutics Inc是一家生物制药公司,专注于开发和商业化治疗转移性疾病的药物。该公司已经开发了一种模块化的、基于氧化铁纳米颗粒的纳米载体系统,用于向肿瘤输送RNA疗法。该公司的主要候选治疗药物TTX-MC138以microRNA-10b(miRNA-10b)为靶点,microRNA-10b是乳腺癌、胰腺癌、卵巢癌、结肠癌、胶质母细胞瘤等多种癌症转移细胞活力的主要调节因子。其临床前项目包括两个实体瘤项目,如TTX-siPDL1,其为一种基于小干扰RNA(siRNA)的程序性死亡配体1(PD-L1)调节剂,和TTX-siLin28b,其为一种基于siRNA的RNA结合蛋白LIN28B抑制剂。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Philippe P. Calais | CEO & Executive Chairman of the Board | 2025 | 67 |
| Thomas A. Fitzgerald | CFO, President, VP of Administration & Director | 2024 | 74 |
| Anna Moore | Co-Founder, Scientific Advisor & Member of Scientific Advisory Board | 2016 | 64 |
| Erik Manting | Independent Director | 2020 | 55 |
| Magda Marquet | Independent Director | 2021 | 67 |
| Elizabeth Adkins Czerepak | Independent Director | 2025 | 70 |
| Keith T. Flaherty | Member of Advisory Board | - | 55 |
| Lubomir Nechev | Member of Advisory Board | 2021 | - |
| Dejan Juric | Member of Advisory Board | 2021 | - |
| Frank J. Slack | Member of Advisory Board | 2022 | - |
| Phillip D. Zamore | Member of Scientific Advisory Board | 2025 | - |
| Jack E. Stover | Director | 2025 | 73 |